SS-20

LongevityMitochondria-targeted tetrapeptide / researchExperimental

SS-20 is a mitochondria-targeted tetrapeptide in the Mitochondrial Peptide class. Like other Szeto-Schiller peptides, SS-20 concentrates in the inner mitochondrial membrane in a membrane-potential-independent manner. Unlike elamipretide it does not carry the dimethyltyrosine residue responsible for cardiolipin binding and radical scavenging, and reported effects on mitochondrial morphology and bioenergetics appear to proceed through a different mechanism.

Calculate Dose

For research use only.

Key Facts

CAS
736992-19-1
Molecular Weight (MW)
595.7 g/mol
Half-life
FDA status
Not Approved
Administration Route
subcutaneous
Frequency
Last updated
Aug 30, 2026
Reviewed
Aug 30, 2026

Research summary

Mitochondria-targeted tetrapeptide from the same Szeto-Schiller series as elamipretide, distinguished by lacking the dimethyltyrosine residue that gives elamipretide its cardiolipin affinity. Not FDA-approved; preclinical only.

Peptide Library's SS-20 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Protocol

Dosage Range
Frequency
Cycle
Administration Route
subcutaneous
Reconstitution Guide

Sequence & molecular data

Sequence and molecular data for SS-20
Molecular formulaC30H45N9O4
Molecular weight595.7 g/mol
CAS number736992-19-1
PubChem CID10008657
FDA UNIIU260G1W6DY

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Like other Szeto-Schiller peptides, SS-20 concentrates in the inner mitochondrial membrane in a membrane-potential-independent manner. Unlike elamipretide it does not carry the dimethyltyrosine residue responsible for cardiolipin binding and radical scavenging, and reported effects on mitochondrial morphology and bioenergetics appear to proceed through a different mechanism. It is used mainly as a comparator that separates cardiolipin-dependent from cardiolipin-independent effects.

Regulatory & research status

SS-20 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for SS-20
FDA statusNot Approved
Research statusResearch-only compound; no approval pathway listed
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

Benefits

Potential Side Effects

No side effects listed yet for this entry.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

SS-20: frequently asked questions

What is SS-20?

Mitochondria-targeted tetrapeptide from the same Szeto-Schiller series as elamipretide, distinguished by lacking the dimethyltyrosine residue that gives elamipretide its cardiolipin affinity. Not FDA-approved; preclinical only.

How does SS-20 work?

Like other Szeto-Schiller peptides, SS-20 concentrates in the inner mitochondrial membrane in a membrane-potential-independent manner. Unlike elamipretide it does not carry the dimethyltyrosine residue responsible for cardiolipin binding and radical scavenging, and reported effects on mitochondrial morphology and bioenergetics appear to proceed through a different mechanism.

Is SS-20 FDA approved?

No. SS-20 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to SS-20?

Compounds most often compared with SS-20 include MOTS-C, Humanin, Humanin-G (HNG) and Elamipretide (SS-31). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 2

This SS-20 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track SS-20 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →